Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-212 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT07793435Phase 2Not yet recruiting
- Sponsor
- Adicet Bio
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ADI-212 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Adicet Bio. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ADI-212
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07793435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793435.